プラバスタチン
|
|
|
- CAS番号.
- 81093-37-0
- 化学名:
- プラバスタチン
- 别名:
- (1S,βR,δR,8aβ)-1,2,6,7,8,8a-ヘキサヒドロ-β,δ,6β-トリヒドロキシ-2β-メチル-8α-[(S)-2-メチル-1-オキソブトキシ]-1β-ナフタレンヘプタン酸;プラバスタチン
- 英語名:
- Pravastatin
- 英語别名:
- MEVALOTIN;PRAVACHOL;ELISOR;KOPOSTAT;Pravatatin;PRAVASELECT;PRAVASTATIN;Pravastatin-D9;PRAVASTATIN(RG);EPTASTATIN SODIUM
- CBNumber:
- CB6317122
- 化学式:
- C23H36O7
- 分子量:
- 424.53
- MOL File:
- 81093-37-0.mol
|
プラバスタチン 物理性質
- 融点 :
- 171.2-173 °C
- 沸点 :
- 634.5±55.0 °C(Predicted)
- 比重(密度) :
- 1.21±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- Sealed in dry,Room Temperature
- 溶解性:
- H2O: 19 mg/mL
- 酸解離定数(Pka):
- 4.31±0.10(Predicted)
- 外見 :
- 粉
- 色:
- 白い
- CAS データベース:
- 81093-37-0(CAS DataBase Reference)
- EPAの化学物質情報:
- 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-.beta.,.delta.,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (.beta.R,.delta,R,1S,2S,6S,8S,8aR)- (81093-37-0)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01CAY10010342 |
Pravastatin |
81093-37-0 |
10mg |
￥9500 |
2023-06-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01CAY10010342 |
Pravastatin |
81093-37-0 |
25mg |
￥20900 |
2023-06-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01CAY10010342 |
Pravastatin |
81093-37-0 |
50mg |
￥34700 |
2023-06-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01CAY10010342 |
Pravastatin |
81093-37-0 |
100mg |
￥59900 |
2023-06-01 |
購入 |
プラバスタチン 化学特性,用途語,生産方法
効能
脂質異常症治療薬, HMG-CoA還元酵素阻害薬
説明
Pravastatin is the third HMG-CoA reductase inhibitor introduced for the treatment of
atherosclerosis. Compared with lovastatin and simvastatin launched earlier, pravastatin is
equipotent as an HMG-CoA reductase inhibitor in vitro, yet it is reported to be more
tissue-selective.
化学的特性
Off-white Cryst
使用
antiglaucoma,
一般的な説明
Pravastatin, sodium 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoate (Pravachol), is the most rapid actingof the three HMG-CoA reductase inhibitor drugs, reachinga peak concentration in about 1 hour. The sodium salt of theβ-hydroxy acid is more hydrophilic than the lactone forms ofthe other two agents, which may explain this property. In addition,the open form of the lactone ring contributes to a morehydrophilic agent, which, in turn, results in less CNS penetration.This explains, in part, why pravastatin has fewer CNSside effects than the more lipophilic lactone ester of this classof agents. Absorption of pravastatin following oral administrationcan be inhibited by resins such as cholestyramine becauseof the presence of the carboxylic acid function on thedrug. The lactone forms of lovastatin and simvastatin are lessaffected by cholestyramine.
プラバスタチン 上流と下流の製品情報
原材料
準備製品
プラバスタチン 生産企業
Global( 159)Suppliers
81093-37-0(プラバスタチン)キーワード:
- 81093-37-0
- KOPOSTAT
- PRAVASTATIN
- PRAVASELECT
- ELISOR
- EPTASTATIN SODIUM
- (BETA R,DELTA R,1S,2S,6S,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-1-NAPHTHALENEHEPTANOIC ACID MONOSODIUM SALT
- (BETAR, DELTAR,1S,2S,6S,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-BETA, DELTA,6-TRIHYDROXY-2-METHYL-8[(2S)-2-METHYL-1-OXOBUTOXYL]-1-NAPHTHALENEHEPTANOIC ACID SODIUM
- (BETA-R,DELTA-R,1S,2S,6S,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8[(2S)-2-METHYL-1-OXOBUTOXYL]-1-NAPHTHALENEHEPTANOIC ACID NA
- [1s-[1a(bs,ds),2a,6b,8b(r),8aa]]-1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid monosodium salt
- (+)-(3r,5r)-3,5-dihydroxy-7-[(1s,2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-[(s)-2-methylbutyryloxy]-1,2,6,7,8,8a-hexahydro-1-naphthyl]-heptanoic acid
- 3BETA-HYDROXYCOMPACTIN, NA
- (3R,5R)-7-[(1S,2R,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoic acid
- PRAVASTATIN(RG)
- 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, [1S-[1a(bS*,dS*),2a,6a,8b(R*),8aa]]-
- 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (bR,dR,1S,2S,6S,8S,8aR)- (9CI)
- 3b-Hydroxycompactin
- PRAVASTATIN FREE BASE
- Pravatatin
- 3β-Hydroxycompactin Sodium salt
- sodium(+)-(3R，5R)-3，5-Dihydroxy-7-[(1S，2S，6S，8αR)-6-hydroxy-2-methyl-8-[(S)-2-methyl-hutyryloxy]1，2，6，7，8，8α-hexahydro-1-naphthyl]heptanoate
- (1S,βR,δR,8aβ)-1,2,6,7,8,8a-Hexahydro-β,δ,6β-trihydroxy-2β-methyl-8α-[(S)-2-methyl-1-oxobutoxy]-1β-naphthaleneheptanoic acid
- Pravastatin-D9
- (3R,5R)-3,5-dihydroxy-7-((1S,2S,6S,8S,8aR)-6-hydroxy-2-Methyl-8-(((S)-2-Methylbutanoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid
- PRAVASTATIN (CS-514)
- (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S)-6-hydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
- 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)-
- Pravastatin USP/EP/BP
- PravastatinQ: What is
Pravastatin Q: What is the CAS Number of
Pravastatin
- MEVALOTIN
- PRAVACHOL
- (1S,βR,δR,8aβ)-1,2,6,7,8,8a-ヘキサヒドロ-β,δ,6β-トリヒドロキシ-2β-メチル-8α-[(S)-2-メチル-1-オキソブトキシ]-1β-ナフタレンヘプタン酸
- プラバスタチン
- 酵素阻害剤
- 抗コレステロール薬
- 脂質低下薬